Next Article in Journal
Boosting Antimicrobial Activity of Ciprofloxacin by Functionalization of Mesoporous Silica Nanoparticles
Next Article in Special Issue
Efficient Ocular Delivery of VCP siRNA via Reverse Magnetofection in RHO P23H Rodent Retina Explants
Previous Article in Journal
Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography
Previous Article in Special Issue
Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types
 
 
Review

Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye

1
A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
2
Department of Ophthalmology, Kuopio University Hospital, 70211 Kuopio, Finland
3
Gene Therapy Unit, Kuopio University Hospital, 70211 Kuopio, Finland
*
Author to whom correspondence should be addressed.
Academic Editor: Francisco Javier Otero-Espinar
Pharmaceutics 2021, 13(2), 219; https://doi.org/10.3390/pharmaceutics13020219
Received: 22 December 2020 / Revised: 31 January 2021 / Accepted: 2 February 2021 / Published: 5 February 2021
(This article belongs to the Special Issue Advances in the Delivery of DNA and RNA Therapeutics to the Eye)
Pathological vessel growth harms vision and may finally lead to vision loss. Anti-angiogenic gene therapy with viral vectors for ocular neovascularization has shown great promise in preclinical studies. Most of the studies have been conducted with different adeno-associated serotype vectors. In addition, adeno- and lentivirus vectors have been used. Therapy has been targeted towards blocking vascular endothelial growth factors or other pro-angiogenic factors. Clinical trials of intraocular gene therapy for neovascularization have shown the treatment to be safe without severe adverse events or systemic effects. Nevertheless, clinical studies have not proceeded further than Phase 2 trials. View Full-Text
Keywords: gene therapy; ocular neovascularization; viral vectors; preclinical; clinical trials; anti-angiogenesis; adeno-associated virus gene therapy; ocular neovascularization; viral vectors; preclinical; clinical trials; anti-angiogenesis; adeno-associated virus
Show Figures

Figure 1

MDPI and ACS Style

Koponen, S.; Kokki, E.; Kinnunen, K.; Ylä-Herttuala, S. Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye. Pharmaceutics 2021, 13, 219. https://doi.org/10.3390/pharmaceutics13020219

AMA Style

Koponen S, Kokki E, Kinnunen K, Ylä-Herttuala S. Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye. Pharmaceutics. 2021; 13(2):219. https://doi.org/10.3390/pharmaceutics13020219

Chicago/Turabian Style

Koponen, Sanna, Emmi Kokki, Kati Kinnunen, and Seppo Ylä-Herttuala. 2021. "Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye" Pharmaceutics 13, no. 2: 219. https://doi.org/10.3390/pharmaceutics13020219

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop